Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 7.75-7.85 for the period, compared to the Thomson Reuters consensus estimate of $7.26. The company issued revenue guidance of $2.869995-2.896205 billion, compared to the consensus revenue estimate of $2.85 billion.
NYSE:CRL opened at $222.00 on Thursday. Charles River Laboratories International has a 52-week low of $95.58 and a 52-week high of $250.29. The business’s fifty day moving average is $227.56 and its 200 day moving average is $192.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.46 and a current ratio of 1.70. The firm has a market cap of $11.03 billion, a price-to-earnings ratio of 40.88, a PEG ratio of 2.29 and a beta of 1.14.
Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $1.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.31. Charles River Laboratories International had a return on equity of 21.58% and a net margin of 9.87%. The business had revenue of $682.60 million during the quarter, compared to analysts’ expectations of $638.70 million. During the same period in the previous year, the business earned $1.63 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. Equities analysts predict that Charles River Laboratories International will post 7.27 EPS for the current fiscal year.
In other Charles River Laboratories International news, Director Stephen D. Chubb sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $217.65, for a total transaction of $217,650.00. Also, Director George Massaro sold 1,943 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $219.91, for a total value of $427,285.13. Following the transaction, the director now directly owns 11,384 shares of the company’s stock, valued at approximately $2,503,455.44. The disclosure for this sale can be found here. Insiders have sold a total of 6,195 shares of company stock valued at $1,345,601 in the last ninety days. 1.90% of the stock is currently owned by corporate insiders.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Further Reading: Dead Cat Bounce
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.